Cardiovascular disease (CVD) comprehensively describes a range of pathologies of the heart and/or blood vessels. These disorders differ markedly in time-scale of development, and relative contributory effects of genes and environment. Largely due to this breadth, and their causes and effects, the range of investigation, assessment, and treatment strategies available is large. The diversity of the diseases, disease processes, and genetic differences between individuals could obscure disease associations in terms of the proteomic signatures of each disorder. Thus, a panel of independent disease-related proteins considered together should be less prone to this noise and help provide much more robust analysis and indication of disease. The publication featured below and the reagents (multi-plex immunoassays or single target ELISA and antibodies) mentioned in this post may contribute in helping you to identify such diseases signature. [Read more…]
Diabetes is a major health concern. And its research can be a nightmare sometimes. tebu-bio strive to offer a comprehensive range of research tools and services to study Obesity, Diabetes, and Metabolic syndrome (including pancreatic islet cells), and tools to unravel signaling mechanisms in insulin secretion. Anyhow, it might be good, though, to go back to the basics from time to time. Let’s remember our graduate courses (more or less years ago) about Insulin and its biological roles.
Apolipoproteins, with amphipathic properties, form lipoprotein particles with phospholipids and transport hydrophobic lipids through lymphatic and blood circulations to designated peripheral tissues or organs for energy supply, biomolecule synthesis, or degradation. Off-balance of apolipoproteins has been implicated in numerous diseases such as SLE, myocardial infarction, Alzheimer’s, and diabetes. Apolipoproteins emerge as risk markers to pinpoint different diseases.
For Cardiovascular diseases, apoF and apoB seem to have a predominant role. [Read more…]
Cardiotrophin-1 (CT-1) is a cardiac hypertrophic factor with cardiac myocyte protective properties. CT-1 belongs to the interleukin-6 cytokine family and acts through LIF receptor ß/glycoprotein 130 (gp130)-coupled signaling pathways.
CT-1 intracellular signaling pathways enlist kinases (ERK, MAP, JAK) but also STAT and PI3-kinase/Akt systems.
Cardiac CT-1 expression is increased by hypoxia, where it protects cardiac myocytes from ischemic injury and apoptosis.